{"entity":{"id":"nct07522151","kind":"trial","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","aka":[],"tldr":"A phase 3 trial of Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.","summary":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer is a phase 3 interventional study registered as NCT07522151 by Shanghai Shengdi Pharmaceutical Co., Ltd, with 874 participants planned, started 2026-05-07 and due to reach its primary completion in 2029-12. Interventions recorded: Adebrelimab plus S-1 and oxaliplatin and Adebrelimab blank preparation plus S-1 and oxaliplatin..","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07522151","url":"https://clinicaltrials.gov/study/NCT07522151"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["adebrelimab","oxaliplatin"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07522151","phase":"3","setting":"A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","enrolled":874,"outcomes":[]},"route":"/trials/nct07522151/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}